CLINICAL_TRIALS ClinicalTrials.gov record update

Phase I Trial of Fenretinide (4-HPR, NSC 374551) Lym-X-Sorb™ (LXS) Oral Powder (4-HPR/LXS Oral Powder) (4-HPR) in Adults With Solid Tumors and Lymphomas

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT00589381
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:35:12.143678+00:00
Published At: 2012-03-08T00:00:00+00:00
Record Updated At: 2012-03-08
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Lymphoma", "Unspecified Adult Solid Tumor, Protocol Specific"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2012-03-08"
protocolSection.identificationModule.nctId: "NCT00589381"
protocolSection.identificationModule.officialTitle: "Phase I Trial of Fenretinide (4-HPR, NSC 374551) Lym-X-Sorb\u2122 (LXS) Oral Powder (4-HPR/LXS Oral Powder) (4-HPR) in Adults With Solid Tumors and Lymphomas"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.